Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial

Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open forum infectious diseases 2015-12, Vol.2 (suppl_1)
Hauptverfasser: Dejesus, Edwin, Gallant, Joel, Shalit, Peter, Cao, Huyen, Liu, Ya-Pei, Myers, Joel, Rosenblatt, Lisa, Yang, Lingfeng, Szwarcberg, Javier
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue suppl_1
container_start_page
container_title Open forum infectious diseases
container_volume 2
creator Dejesus, Edwin
Gallant, Joel
Shalit, Peter
Cao, Huyen
Liu, Ya-Pei
Myers, Joel
Rosenblatt, Lisa
Yang, Lingfeng
Szwarcberg, Javier
description
doi_str_mv 10.1093/ofid/ofv133.622
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ofid_ofv133_622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_ofid_ofv133_622</sourcerecordid><originalsourceid>FETCH-LOGICAL-c812-1b1351524444ff299b03be772350f2a74ac577ffc11b1457d1bfd6bab2cacfc43</originalsourceid><addsrcrecordid>eNpdUU1P3DAQjVArgYBzr3Nk1Q3rj4RsegtZtq2EVEQjOEZjxy5uvfHKdlbAT-dUr5ZD1TnMzJt586TRy7JPlFxSUvOF02ZIaUc5v7xi7Cg7YZwt82VdVh_-6Y-z8xB-E0IoJSWp6pPsrYn4iiPujIc7OwVonTDShIgRLpruAT6DnMGD8iHt_ufem-gO8J3qZ3O4dvEJzJiENsKMGI0b4dGk2c0m-iQdMY3VolOj025_uzLBbb17NhbW0wY9RgUX665ddKv17As8KvUHiiX8nMQv76YtNCPal2ACOA0Id08YFPA53OM4uI15VcMcVm4SVuXX1owJNTKancpbN0bvrFUDdN6gPcs-arRBnb_X06xb33Ttt_z2x9fvbXObyyVlORWUl7RkRQqtWV0LwoWqKsZLohlWBcqyqrSWNDGLshqo0MOVQMEkSi0LfpotDrLSuxC80v3Wm_TmS09Jvzev35vXH8zrk3n8L7n-kD0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Dejesus, Edwin ; Gallant, Joel ; Shalit, Peter ; Cao, Huyen ; Liu, Ya-Pei ; Myers, Joel ; Rosenblatt, Lisa ; Yang, Lingfeng ; Szwarcberg, Javier</creator><creatorcontrib>Dejesus, Edwin ; Gallant, Joel ; Shalit, Peter ; Cao, Huyen ; Liu, Ya-Pei ; Myers, Joel ; Rosenblatt, Lisa ; Yang, Lingfeng ; Szwarcberg, Javier</creatorcontrib><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofv133.622</identifier><language>eng</language><ispartof>Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Dejesus, Edwin</creatorcontrib><creatorcontrib>Gallant, Joel</creatorcontrib><creatorcontrib>Shalit, Peter</creatorcontrib><creatorcontrib>Cao, Huyen</creatorcontrib><creatorcontrib>Liu, Ya-Pei</creatorcontrib><creatorcontrib>Myers, Joel</creatorcontrib><creatorcontrib>Rosenblatt, Lisa</creatorcontrib><creatorcontrib>Yang, Lingfeng</creatorcontrib><creatorcontrib>Szwarcberg, Javier</creatorcontrib><title>Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial</title><title>Open forum infectious diseases</title><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpdUU1P3DAQjVArgYBzr3Nk1Q3rj4RsegtZtq2EVEQjOEZjxy5uvfHKdlbAT-dUr5ZD1TnMzJt586TRy7JPlFxSUvOF02ZIaUc5v7xi7Cg7YZwt82VdVh_-6Y-z8xB-E0IoJSWp6pPsrYn4iiPujIc7OwVonTDShIgRLpruAT6DnMGD8iHt_ufem-gO8J3qZ3O4dvEJzJiENsKMGI0b4dGk2c0m-iQdMY3VolOj025_uzLBbb17NhbW0wY9RgUX665ddKv17As8KvUHiiX8nMQv76YtNCPal2ACOA0Id08YFPA53OM4uI15VcMcVm4SVuXX1owJNTKancpbN0bvrFUDdN6gPcs-arRBnb_X06xb33Ttt_z2x9fvbXObyyVlORWUl7RkRQqtWV0LwoWqKsZLohlWBcqyqrSWNDGLshqo0MOVQMEkSi0LfpotDrLSuxC80v3Wm_TmS09Jvzev35vXH8zrk3n8L7n-kD0</recordid><startdate>20151209</startdate><enddate>20151209</enddate><creator>Dejesus, Edwin</creator><creator>Gallant, Joel</creator><creator>Shalit, Peter</creator><creator>Cao, Huyen</creator><creator>Liu, Ya-Pei</creator><creator>Myers, Joel</creator><creator>Rosenblatt, Lisa</creator><creator>Yang, Lingfeng</creator><creator>Szwarcberg, Javier</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20151209</creationdate><title>Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial</title><author>Dejesus, Edwin ; Gallant, Joel ; Shalit, Peter ; Cao, Huyen ; Liu, Ya-Pei ; Myers, Joel ; Rosenblatt, Lisa ; Yang, Lingfeng ; Szwarcberg, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c812-1b1351524444ff299b03be772350f2a74ac577ffc11b1457d1bfd6bab2cacfc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dejesus, Edwin</creatorcontrib><creatorcontrib>Gallant, Joel</creatorcontrib><creatorcontrib>Shalit, Peter</creatorcontrib><creatorcontrib>Cao, Huyen</creatorcontrib><creatorcontrib>Liu, Ya-Pei</creatorcontrib><creatorcontrib>Myers, Joel</creatorcontrib><creatorcontrib>Rosenblatt, Lisa</creatorcontrib><creatorcontrib>Yang, Lingfeng</creatorcontrib><creatorcontrib>Szwarcberg, Javier</creatorcontrib><collection>CrossRef</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dejesus, Edwin</au><au>Gallant, Joel</au><au>Shalit, Peter</au><au>Cao, Huyen</au><au>Liu, Ya-Pei</au><au>Myers, Joel</au><au>Rosenblatt, Lisa</au><au>Yang, Lingfeng</au><au>Szwarcberg, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial</atitle><jtitle>Open forum infectious diseases</jtitle><date>2015-12-09</date><risdate>2015</risdate><volume>2</volume><issue>suppl_1</issue><issn>2328-8957</issn><eissn>2328-8957</eissn><doi>10.1093/ofid/ofv133.622</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2328-8957
ispartof Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)
issn 2328-8957
2328-8957
language eng
recordid cdi_crossref_primary_10_1093_ofid_ofv133_622
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central
title Atazanavir Plus Cobicistat (ATV + c) Versus Atazanavir Plus Ritonavir (ATV + r), Both in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): Week 48 Subgroup Analysis of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A22%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atazanavir%20Plus%20Cobicistat%20(ATV%20+%20c)%20Versus%20Atazanavir%20Plus%20Ritonavir%20(ATV%20+%20r),%20Both%20in%20Combination%20With%20Emtricitabine/Tenofovir%20Disoproxil%20Fumarate%20(FTC/TDF):%20Week%2048%20Subgroup%20Analysis%20of%20a%20Phase%203,%20Randomized,%20Double-Blind,%20Active-Controlled%20Trial&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Dejesus,%20Edwin&rft.date=2015-12-09&rft.volume=2&rft.issue=suppl_1&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofv133.622&rft_dat=%3Ccrossref%3E10_1093_ofid_ofv133_622%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true